Aclaris Therapeutics Inc
Abierto
4.43 3.02
Resumen
Variación precio
24h
Mínimo
4.3
Máximo
4.53
Ingresos | -29K -20M |
|---|---|
Ventas | 701K 2M |
BPA | -0.15 |
Margen de beneficios | -993.186 |
Empleados | 69 |
EBITDA | -2.5M -22M |
Recomendaciones | Compra Fuerte |
|---|---|
Estimación a 12 Meses | +146.99% upside |
Próximas Ganancias | 5 ago 2026 |
|---|
Capitalización Mercado | -24M 609M |
|---|---|
Apertura anterior | 1.41 |
Cierre anterior | 4.43 |
Aclaris Therapeutics Inc Gráfico
Resultados pasados no son un indicador fiable de resultados futuros.
Acerca de Aclaris Therapeutics Inc
Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.